TY - JOUR T1 - Epigenomic profiles of African American <em>Transthyretin</em> Val122Ile carriers reveals putatively dysregulated amyloid mechanisms JF - medRxiv DO - 10.1101/2020.04.15.20066621 SP - 2020.04.15.20066621 AU - Gita A Pathak AU - Frank R Wendt AU - Antonella De Lillo AU - Yaira Z. Nunez AU - Aranyak Goswami AU - Flavio De Angelis AU - Maria Fuciarelli AU - Henry R Kranzler AU - Joel Gelernter AU - Renato Polimanti Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/18/2020.04.15.20066621.abstract N2 - The Val122Ile mutation in Transthyretin (TTR) gene causes a rare, difficult to diagnose hereditary form of cardiac amyloidosis. This mutation is most common in the United States and mainly present in people of African descent. The carriers have an increased risk of congestive heart failure and several other non-cardiac phenotypes such as carpal tunnel syndrome, peripheral edema, and arthroplasty which are top reasons for ambulatory/outpatient surgeries in the country. We conducted first-ever epigenome-wide association study in Val122Ile carriers of African descent for heart disease (HD) and multiple outpatient surgeries (OS) - an early disease indicator. Five differentially methylated sites (p≤2.1e-08) in genes – FAM129B, SKI, WDR27, GLS, and an intergenic site near RP11-550A5.2 and one differentially methylated region containing KCNA6 and GALNT3 (p=1.1e-12) were associated with HD. For OS, we observe four sites – two sites in UBE2E3 and SEC14L5, and other two in intergenic regions (p≤1.8e-07) and three regions overlapping SH3D21, EVA1B, LTB4R2 and CIDEB (p≤3.9e-07). Functional PPI module analysis identified ABCA1 (p=0.001) for HS. Six cis-mQTLs were associated with one of the significant CpG sites (FAM129B; p=4.1e-24). We replicated two CpG sites (cg18546846 and cg06641417; p&lt;0.05) in an external cohort of biopsy-confirmed cases of TTR amyloidosis. The genes identified are involved in transport and clearance of amyloid deposits (GLS, ABCA1, FAM129B); cardiac fibrosis (SKI); and muscle tissue regulation (SKI, FAM129B). These findings highlight the link between a complex amyloid circuit and diverse symptoms of Val122Ile.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by ‘Global ASPIRE TTR Amyloidosis Competitive Grant’ from Pfizer Inc. We are grateful to the participants of the Yale-Penn cohort, which was funded under grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01AA11330, and R01 AA017535. The investigation conducted in the Italian cohort was supported by an Investigator-Initiated Research from Pfizer Inc. to the University of Rome “Tor Vergata”. The content reported in the manuscript is solely the responsibility of the authors and does not represent the official views of the NIH or Pfizer. The funding agencies had no role in the study design, data analysis, and results interpretation of the present study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull summary statistics of the epigenome-wide analysis will be made available post-publication by contacting the corresponding author – R.P. listed on the manuscript. ER -